
Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19

Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19
The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial
Eur J Integr Med. 2021 Feb; 42: 101305.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Sixty patients with severe COVID-19 were randomized to receive routine care plus intravenous Xuebijing injection (n=30) or routine care alone (n=30) for the suppression of inflammatory response and management of symptoms. The primary outcome of interest was peripheral blood lymphocyte and interleukin (IL)-6 levels which were measured at 1, 7 and 14 days follow-up. Secondary outcomes of interest in...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Join the Conversation
Please Login or Join to leave comments.